Tag Archives: (ABT)

Sugar-Coating Nothing

Last week, I found myself sitting across from a former Abbott (ABT) executive at a quiet corner table in Chicago’s Union League Club, listening to something that made my biochemistry background tingle with excitement. We were discussing the recent market pummeling of Abbott shares following their third-quarter earnings, and he leaned forward with that conspiratorial […]

Built For Droughts

Let me tell you about my neighbor’s irrigation system. Five years ago, he spent a small fortune installing drip lines throughout his property. While everyone was comparing rose bushes and lawn ornaments, he was investing in a system that would never make the front page of the HOA newsletter but would save him a fortune. […]

When The Market Gives Back What It Once Took Away

If Wall Street had a confessional booth, I’d be first in line. “Forgive me, market gods, for I underestimated how quickly sentiment could shift.” When I last wrote about Abbott Laboratories (ABT), the market was treating this medical device powerhouse like last week’s leftovers—despite growth that would make most CEOs weep with joy. Fast forward […]